Navigation Links
Pressure Ridge Single Plate Molteno Implant (D1)

ProductsPressure Ridge Single Plate Molteno Implant (D1)
Company Molteno Ophthalmic Limited
Item Pressure Ridge Single Plate Molteno Implant (D1)
Features The subsidiary ridge on this implant, when covered by Tenons capsule, acts as a pressure sensitive biological valve which limits the escape of aqueous from the eye and reduces postoperative hypotony. This Molteno Implant is particularly suitable for neovascular glaucomas, acute glaucomas in patients with reduced ciliary body function, elderly patients and combined cataract and glaucoma procedures.
Description Long-term biocompatibility is established. Provides a robust and durable drainage system. Preplaced suture holes ensure correct positioning on the globe. Pressure Ridge Molteno Implants have a subsidiary ridge which, when covered by Tenons tissue, acts as a Pressure sensitive biological valve, limiting postoperative hypotony. The range of implants allows the surgeon to choose the drainage area according to the severity of the glaucoma. Double Plate Molteno Implants have twice the drainage area of Single Plate Molteno Implants. The twin plate design gives a large drainage area while avoiding interference with the extraocular muscles. Choice of left or right eye configurations. Insertion is well described and straightforward. The surgeon may select from a variety of ligature or stent procedures to improve the control of postoperative hypotony and bleb fibrosis.
Info Molteno Ophthalmic Limited
Customer Service: 64 3 4792744
Web site: http://www.molteno.com/

Related medicine products :

1. Pressure Ridge Double Plate Molteno Implant (DR2/DL2)
2. Ventrix™ NL950-100 Intercranial Pressure Monitoring System
3. Sophy Adjustable Pressure Valves
4. WaveMap™ & SmartWire™ Pressure System
5. Smartmap Pressure Instrument
6. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters; SPC-721
7. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters; SPC-771
8. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters; SPC-771S
9. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters with Lumen; SPC-770
10. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters with Lumen; SPC-780C
11. Dual Pressure Sensor Intravascular Mikro-Tip Pressure Catheters with Lumen; SPC-784A
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
... laboratory and a worldwide leader in innovative l... extensive test menu of highly complex and unique ...Owned by the University of Utah, ARUP Laboratories...niversity teaching hospitals and children's hospit...
Medicine Products:
(Date:7/25/2008)...erican Society for Gastrointestinal Endoscopy (ASG...in the bariatric surgery patient. The rising preva...ess in surgical interventions led to a marked incr...med in the U.S., from 13,365 in 1998 to 102,794 in...operative patient and the postoperative patient, a...
(Date:7/25/2008)...er of jobs created in the medical field slowed in ...t kind of slowdown: they laid off fewer people in ... Seattle, WA (PRWEB) July 25, 2008 -- Though...lowed in June overall, pharmaceutical companies re...usic to the ears of sales representatives: fewer l...
(Date:7/25/2008)...xclusivity Begins -, CORONA, Calif., July 25 /PRN... (NYSE: WPI ), a leading specialty pharmaceutical...commenced commercial,shipment of its Omeprazole De...ength from its Davie, Florida manufacturing facili... days of marketing exclusivity for being the,first...
(Date:7/25/2008).../ -- Sagent Pharmaceuticals, Inc.,a privately-hel...d that it,has launched amiodarone HCl injection, U...reatment and prophylaxis of frequently recurring,v...le ventricular,tachycardia -- a potentially life-t...ne HCl injection will be available immediately in ...
Breaking Medicine News(10 mins):Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 2Health News:ASGE issues guidelines on the role of endoscopy in the bariatric surgery patient 3Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 2Health News:The MedZilla Report: June 2008 Employment Outlook for Biotech/Pharma/Health 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 2Health News:Sagent Pharmaceuticals Launches Amiodarone HCl Injection, USP 3
... put on the national agenda by India's political l...re pressing problems. // Sam Pitroda was right in... for selecting students for institutions of higher... of increasing the number of Indian Institutes of ...
...alth Organization (WHO), Dr Anders Nordstrom, addr... office // , confirmed that Dr Anders Nordstrom. H...l resources and the support from the people to con...ria and polio. He reiterated that he would contin...
...IDS. It is waiting for the FDA to give it an appro... company already sells the kit to hospitals and pu...ug Michels, thinks that this product would become ...lmost 25 years since the first AIDS diagnosis was ...
...new strain of E. coli O157was responsible for the ... in Europe and Australia, but is apparently very r...ntly in the laboratory from other types of E.coli ...d in finding out more about it,' said HPS consulta...
Other Medicine News:Health News:Quota System: Diverting Attention From The Real Problem 2Health News:Quota System: Diverting Attention From The Real Problem 3Health News:Quota System: Diverting Attention From The Real Problem 4
(Date:7/24/2008)...wswire-USNewswire/ -- Headlines claiming "soy,prod...y. The small scale,preliminary study that Dr. Jor...n, is based on recollected intake of soyfoods and ...tudy is confounded by many,issues, thus I feel the...tion," warned Dr. Tammy Hedlund, a researcher in p...
(Date:7/24/2008)...wire-FirstCall/ -- MacroChem Corporation (OTC,Bull...se 2 clinical trial,involving 37 patients who comp...icacy and safety study of EcoNail, a topical antif...nail fungus). The composite,primary efficacy endpo...gative mycology (negative fungal culture and negat...
(Date:7/23/2008)...lication in July print edition of Clinical ...APOLIS, July 23 /- A Roche Diagnostic...rminal pro-B-type natriuretic peptide,(NT-proBNP) ...,stratification in predicting the risk of cardiova...with non-steroidal anti-inflammatory drugs of,the ...
(Date:7/23/2008)...re/ -- FluoroPharma Inc., a company developing,bre...n Emission Tomography,(PET) market, announced posi...-18 labeled tracer for myocardial perfusion imagin...roduct to complete Phase I clinical,development., ...the blood flow in the,heart (myocardial perfusion)...
Breaking Medicine Technology:Soyfoods Do Not Impact Sperm Count 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 2MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 3MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 4MacroChem Announces Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis 5Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 2Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 3Study Reveals Potential for NT-proBNP as a Marker to Predict Cardiovascular Risks From Anti-Inflammatory Drugs 4FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 2FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET) 3Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy 3713 1Concentra Medical Centers Gears Up for Flu Season to Keep Area Workforce Healthy 3713 2Easter Seals Awards State and Municipal Public Officials With 2007 Outstanding Advocate Awards 3711 1Easter Seals Awards State and Municipal Public Officials With 2007 Outstanding Advocate Awards 3711 2James B Hawkins Appointed to IRIDEX Board of Directors 3709 1James B Hawkins Appointed to IRIDEX Board of Directors 3709 2James B Hawkins Appointed to IRIDEX Board of Directors 3709 3The First Mega Shelter Arrangement in Oregon Created for Major Disaster Response and Recovery 3707 1The First Mega Shelter Arrangement in Oregon Created for Major Disaster Response and Recovery 3707 2The First Mega Shelter Arrangement in Oregon Created for Major Disaster Response and Recovery 3707 3
...Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI), ...he American Academy of Allergy, Asthma, and,Immuno... The,posters discussed findings from a survey of 2...U.S., U.K., France, and Germany on the,burden of c... of,the fungal etiology of CS, and the differences...
...- Advanced Viral,Research Corp. (OTC Bulletin Boar...oday that new information on AVR118 has been,accep... American,Society of Clinical Oncology (ASCO) Abst...uted to the nearly 25,000 oncology,practioners who...on,June 1-5., Based on recent work conducted by AD...
Other Medicine Technology:Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 2American Society of Clinical Oncology (ASCO) Accepts New Data on,AVR118 for Publication in 2007 Abstract Book 3